XML 82 R60.htm IDEA: XBRL DOCUMENT v3.24.1.1.u2
BUSINESS COMBINATION (Details Narrative) - USD ($)
3 Months Ended
Feb. 14, 2024
Mar. 31, 2024
Mar. 31, 2023
Issuance of Series A preferred stock, shares   164,614,418  
Transaction costs $ 7,728,681    
Transaction costs $ 229,328 $ 7,499,353
Charged expense   $ 7,499,353  
Earnout Shares [Member]      
Earnout shares   24,500,000  
Tevogen Bio [Member]      
Ownership percentage   91.00%